Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

The Centers for Medicare and Medicaid Services (CMS) released its second round of drug negotiation targets, a list of 15 ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The Biden administration says popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Popular but pricey weight-loss drugs Ozempic and Wegovy are among the 15 medications whose prices will be subject to direct negotiations between Medicare and drug makers.